AC Immune SA (ACIU)

AC Immune Income Statement

Financials in millions CHF. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	14.8	14.8	3.94	0	15.43	110.46
Revenue Growth (YoY)	276.14%	276.14%	-	-	-86.03%	1498.03%
Gross Profit	14.8	14.8	3.94	0	15.43	110.46
Selling, General & Admin	16.17	15.31	15.79	17.91	18.56	16.06
Research & Development	55.9	54.61	60.34	62.28	59.49	50.43
Other Operating Expenses	-1.15	-1.49	-1.34	-1.18	-1.35	-0.57
Operating Expenses	70.92	68.43	74.78	79.01	76.69	65.92
Operating Income	-56.12	-53.62	-70.85	-79.01	-61.26	44.54
Interest Expense / Income	0.12	0.18	0.36	0.58	0.18	1.93
Other Expense / Income	-1.66	0.42	-0.46	-6.6	0.48	-2.83
Pretax Income	-54.58	-54.22	-70.74	-72.99	-61.92	45.44
Income Tax	0.01	0.01	0.01	0	0	0
Net Income	-54.58	-54.23	-70.75	-73	-61.92	45.44
Shares Outstanding (Basic)	99	85	84	73	72	68
Shares Change	18.63%	0.30%	15.88%	1.43%	6.36%	17.80%
EPS (Basic)	-0.61	-0.64	-0.85	-0.97	-0.86	0.64
EPS (Diluted)	-0.61	-0.64	-0.85	-0.97	-0.86	0.64
Free Cash Flow	-44.2	-61.63	-74.4	-67.85	-60.89	53.34
Free Cash Flow Per Share	-0.45	-0.73	-0.88	-0.93	-0.85	0.79
Gross Margin	100.00%	100.00%	100.00%	-	100.00%	100.00%
Operating Margin	-379.17%	-362.30%	-1800.43%	-	-396.99%	40.32%
Profit Margin	-368.77%	-366.41%	-1798.04%	-	-401.28%	41.14%
Free Cash Flow Margin	-298.66%	-416.38%	-1890.67%	-	-394.59%	48.29%
EBITDA	-52.26	-51.83	-68.03	-70.01	-59.77	49.06
EBITDA Margin	-353.08%	-350.19%	-1728.74%	-	-387.34%	44.42%
Depreciation & Amortization	2.2	2.22	2.36	2.41	1.97	1.69
EBIT	-54.46	-54.05	-70.39	-72.41	-61.74	47.37
EBIT Margin	-367.95%	-365.16%	-1788.69%	-	-400.08%	42.88%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).